What type of study is this?

This is a Human Clinical Trial study (also classified as: Meta-Analysis, Phase 3).

December 8, 2025BloodOpen Access

Comparative efficacy of novel therapies for sickle cell disease: A network meta-analysis of hydroxyurea, voxelotor, crizanlizumab, and l-glutamine

View Full Paper

Ask AI

Bookmark

Authors

Network meta-analysis compares interventions for sickle cell disease, revealing distinct effects on vaso-occlusive crises and clinical outcomes.

To compare the efficacy of hydroxyurea, voxelotor, crizanlizumab, and L-glutamine for sickle cell disease treatment.
Conducted a systematic literature search across PubMed, Embase, and Cochrane CENTRAL.
Included randomized controlled trials evaluating various therapies for sickle cell disease.
Analyzed outcomes such as vaso-occlusive crises and hemoglobin concentration under a random-effects model.
Hydroxyurea consistently reduced the frequency of vaso-occlusive crises.
L-glutamine showed modest reductions in vaso-occlusive crises and hospitalizations.
Voxelotor increased hemoglobin concentration with limited effects on vaso-occlusive crises.

Kriplani et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Network meta-analysis compares interventions for sickle cell disease, revealing distinct effects on vaso-occlusive crises and clinical outcomes.